This document provides technical guidance for manufacturers seeking World Health Organization (WHO) prequalification of in vitro diagnostic devices (IVDs) for malaria, with a focus on rapid diagnostic tests (RDTs) for symptomatic patients. It summarises the minimum performance requirements, includin...g analytical and clinical performance standards, and emphasises considerations relating to diverse specimen types, testing environments and user populations in low- and middle-income countries. The guidance is aligned with the criteria and prequalification processes of the WHO Global Malaria Programme, while clarifying that demonstration of clinical utility is outside the scope of prequalification.
more
The Mekong Malaria Elimination (MME) programme is an initiative aimed at supporting Greater Mekong Subregion (GMS) countries – Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, and Yunnan (China) – in achieving the goal of malaria elimination by 2030. Data for this epidemi...ological summary were compiled from country reports. Between July and September 2024, 48 115 malaria cases were reported. During that period, GMS countries recorded 44% fewer cases, with P. falciparum + mixed and P. vivax cases declining by 81% and 36%, respectively. Meanwhile, testing declined by 25% when compared to the same period in 2023.
more
This document provides technical guidance for manufacturers seeking World Health Organization (WHO) prequalification of in vitro diagnostic devices (IVDs) for malaria, with a focus on rapid diagnostic tests (RDTs) for symptomatic patients. It summarises the minimum performance requirements, includin...g analytical and clinical performance standards, and emphasises considerations relating to diverse specimen types, testing environments and user populations in low- and middle-income countries. The guidance is aligned with the criteria and prequalification processes of the WHO Global Malaria Programme, while clarifying that demonstration of clinical utility is outside the scope of prequalification.
more
Malaria remains a significant public health concern in the SADC region, accounting for 20% of childhood deaths, as well as prompting numerous outpatient visits and hospitalisations. Around three-quarters of the population, including 35 million children under the age of five and 8.5 million pregnant ...women, are at risk. Transmission patterns vary from high and stable in the north to malaria-free in the south, with low, unstable and seasonal zones in between. Although interventions such as indoor residual spraying (IRS), insecticide-treated nets (ITNs/LLINs), intermittent preventive treatment in pregnancy (IPTp), rapid diagnostic tests (RDTs), and artemisinin-based combination therapies (ACTs) have reduced the malaria burden, challenges persist in terms of funding, human resources, surveillance, and cross-border coordination. Achieving malaria elimination in the SADC region requires harmonised regional standards, strengthened surveillance, and improved access to quality treatment and policy prioritisation.
Accessed on 27/08/2025.
more
En 2024, le Cap-Vert et l’Égypte ont été certifiés exempts de paludisme, ce qui prouve qu'il est possible d'éliminer la maladie avec une volonté politique et des ressources adaptées. Cependant, en Afrique, où se concentrent 95 % des cas mondiaux et 97 % des décès (en 2023), les progrès ...stagnent et l’objectif d’élimination d’ici 2030 est menacé. Les principaux obstacles sont le déficit de financement, la résistance aux insecticides et aux médicaments, l'expansion du moustique Anopheles stephensi, le changement climatique, les crises humanitaires et la croissance démographique. Pour inverser la tendance, l’Afrique doit accélérer le déploiement de nouveaux outils (moustiquaires de nouvelle génération, vaccins), renforcer la mobilisation des ressources nationales et diversifier les financements. Une feuille de route de l’Union africaine vise à transformer ces engagements en actions concrètes pour éliminer le paludisme et ses conséquences sanitaires et économiques.
Accessed 27/08/2025.
more
Tuberculosis (TB) remains a significant global health challenge, with an estimated annual death rate of approximately one per 100,000 people in countries with low TB prevalence. Rapid reductions in TB cases and deaths worldwide depend on research breakthroughs, including the development of new vac...cines. There has recently been an increase in political commitment, as evidenced by two UN high-level meetings on TB in 2018 and 2023. The 2023 political declaration reaffirmed the goals set out in the UN Sustainable Development Goals and the WHO's End TB Strategy, and established new targets for the period 2023–2027
more
This guidance synthesizes current evidence on dengue laboratory testing and diagnostics and provides practical recommendations for laboratories, clinicians, public health officials, and programme managers involved in dengue diagnosis, surveillance, and control, in the context of the global emergency.... It includes a diagnostic algorithm for suspected cases, outlining appropriate testing methods based on days post symptom onset.
more
IDMC's Global Report on Internal Displacement (GRID) is the authoritative source for data and analysis on the state of internal displacement for the previous year.
This report synthesizes the state of knowledge on the interlinkages between environmental degradation climate change conflict and mobility in the East and Horn of Africa, focusing on Burundi, Djibouti, Ethiopia, Kenya, Somalia, South Sudan, Tanzania, and Uganda.
Internal displacements due to conflict and disasters are a major driver of global human mobility. While the total numbers of internal displacements by cause and geographical location are increasingly well tracked, a significant gap remains in the availability of disaggregated data on key variables ... such as age, sex, education, livelihood – for the populations impacted by these events. Data from localised case studies can provide this granularity; however, they are difficult to generalise to other contexts. This lack of disaggregated profiles complicates the work of decision makers tasked with allocating resources efficiently to address the diverse
vulnerabilities and needs of impacted communities
more
Internal displacements due to conflict and disasters are a major driver of global human mobility. While the total numbers of internal displacements by cause and geographical location are increasingly well tracked, a significant gap remains in the availability of disaggregated data on key variables ... such as age, sex, education, livelihood – for the populations impacted by these events. Data from localised case studies can provide this granularity; however, they are difficult to generalise to other contexts. This lack of disaggregated profiles complicates the work of decision makers tasked with allocating resources efficiently to address the diverse
vulnerabilities and needs of impacted communities
more
The health of refugees and migrants is directly related to their access to quality, effective and appropriate health care along all their routes of travel. Refugees and migrants face challenges in accessing health care, including financial, legal and cultural barriers, that are well documented.
Register on the Website for free to receive the weekly briefing
This document outlines the plan for a continental cholera prevention and control with the implementation framework for the Cholera IMST, detailing its governance structure, strategic priorities, and operational modalities
Public health challenges over the past decade have highlighted the importance of approaching health through a holistic lens of human, animal, and environmental sectors, recognizing the need for a collaborative response against shared threats. Zoonotic diseases, transmitted between humans and animals... through their shared environment, are at the forefront of the threats requiring collaborations that span human health, natural ecosystems, and food systems.
more
During the reporting period, significant progress was made in strengthening the mpox response across the continent. The lessons learned and challenges identified during the joint mpox continental intra-action review (IAR), which took place successfully in December 2024 in Addis Ababa have guided the... development of the action plan for the response to the mpox epidemic in January and February 2025.
more
Drawing on the World Health Organization’s package of NCD best buys, the report demonstrates how these evidence-based measures can help countries reduce premature deaths, strengthen health systems, and advance progress towards the Sustainable Development Goals. It provides policymakers, donors, ad...vocates, and partners with a clear economic and social rationale for scaling up implementation of proven solutions. By framing NCD prevention and control as both a health and development priority, the report offers a roadmap for action that delivers benefits across populations, economies, and generations. The evidence is clear: investing in WHO’s best buys is not only possible—it is imperative. The time to act is now.
more
The global cholera statistics for 2024, showing an increase in both the number of people who fell sick and died from the disease.
Reported cholera cases rose by 5% and deaths by 50% in 2024 compared to 2023, with more than 6000 people dying from a disease that is both preventable and treatable. Whi...le these numbers are themselves alarming, they are underestimates of the true burden of cholera.
Weekly epidemiological record WER No 36, 2025, 100, 347–364
more
Access to medicines is essential for attainment of universal health coverage, which is central to achievement of the health-related Sustainable Development Goals. Controlled medicines include those such as opioids, benzodiazepines, barbiturates, amphetamines and others with identified or emergent cl...inical indications. WHO recognizes that these medicines are necessary for pre- and post-operative care, for sedation, for the management of both acute and chronic pain, for palliative care, as anticonvulsants (anti-epileptics), for the management of anxiety disorders and for the management of substance use disorders, including as opioid agonist therapy (OAT).
more